An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
NCT ID: NCT05916157
Last Updated: 2025-05-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
250 participants
OBSERVATIONAL
2023-11-30
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
ABBV-951 is an approved drug being developed for the treatment of PD in Japan. Approximately 250 adult participants over 15 years with a diagnosis of PD who are prescribed ABBV-951 by their physicians will be enrolled in this study across Japan.
Participants will receive ABBV-951 as prescribed their physician and followed for 52 weeks.
There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
NCT04380142
Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease
NCT04379050
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease
NCT04750226
A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment
NCT03374917
A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)
NCT03781167
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ABBV-951
Participants will receive ABBV-951 as prescribed by their physician.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Prescribed ABBV-951 as physicians' decision according to the approved label for treatment of aPD.
* Given informed consent (or by her/his legal representative, if it's a requirement from the participating hospital/clinic) for participating this study.
Exclusion Criteria
* Currently participating in interventional clinical trials.
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saiseikai Matsuyama Hospital /ID# 276259
Matsuyama, Ehime, Japan
National Hospital Organization Asahikawa Medical Center /ID# 269115
Asahikawa, Hokkaido, Japan
Ryugasaki Saiseikai Hospital /ID# 264435
Ryūgasaki, Ibaraki, Japan
University of Tsukuba Hospital /ID# 268353
Tsukuba, Ibaraki, Japan
Okatsu Hospital /ID# 262781
Kagoshima, Kagoshima-ken, Japan
University Hospital Kyoto Prefectural University of Medicine /ID# 267445
Kyoto, Kyoto, Japan
Sendai Nishitaga National Hospital /ID# 268349
Sendai, Miyagi, Japan
Fujimoto General Hospital /ID# 277287
Miyakonojo-shi, Miyazaki, Japan
Shiga University of Medical Science Hospital /ID# 265637
Ōtsu, Shiga, Japan
Dokkyo Medical University Hospital /ID# 269116
Mibu, Tochigi, Japan
Juntendo University Hospital /ID# 264438
Bunkyo-ku, Tokyo, Japan
Nitobe Memorial Nakano General Hospital /ID# 275668
Nakano-ku, Tokyo, Japan
National Center of Neurology and Psychiatry - Kodaira /ID# 267372
Xiaoping City, Tokyo, Japan
National Hospital Organization Utano Hospital /ID# 268350
Kyoto, , Japan
Okayama Neurology Clinic /ID# 269117
Okayama, , Japan
Municipal Toyonaka Hospital /ID# 271277
Toyonaka, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P23-529
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.